Droht Gefahr eines Delistings ? - 500 Beiträge pro Seite

[2Bombi]

So langsam kommen wir in den Bereich wo ein Delisting von der Nasdaq immer möglicher wäre....

Ist das ein Thema ??

Kurs 3Mon. unter 1$ (bei der Marktlage gut möglich)
Umsatz zu gering (bei der Marktlage gut möglich)

was sind denn genau alle Kriterien für ein Delisting ???

[Reiners]

Kannst Du mal bitte ein Foto von Dir "in Aktion" reinstellen.

Danke

LOL

[Reiners]

Sorry falscher Thread

[2Bombi]

wohl nicht oder doch ????

[TheRed]

Wie war das denn noch, nur einen bestimmten Marcet Cap (20 Mio $???), weiß ich aber nicht mehr genau.
Aber auf alle Fälle einen Kurs über einen bestimmten Zeitraum dauerhaft unter 1 $.
Der Kurs passt, aber die Marktkapitalisierung ist wohl noch zu hoch. Kann aber wohl noch werden!

Aber ich denke mal, daß erledigt sich vorher; die haben noch 2,7 Mio $ an Cash (am 31.12.).
Zitat: "The Company estimates that its available cash resources will be sufficient to fund its planned operations through April 2002"
Die müßten eigendlich jetzt schon fast zahlungsunfähig sein.
Das wars dann wohl. Da habe ich mich doch glatt vertan; ich dachte eigendlich, daß die schon im 2-3 Quartal 2001 pleite gehen würden.
Happy trading.

The Red

[TheRed]

Ah, hier habe ich eine passende Meldung gefunden:

"Nasdaq listing rules provide that if the closing bid price of a company’s stock is below $1.00 for more than thirty consecutive trading days, the company faces possible delisting from Nasdaq. Additionally, Nasdaq listing rules require that a company’s stockholder equity be at least $4.0 million, and after October, 2002 be at least $10.0 million."
Vom 11.09.2001-2.01.2002 waren dies Regeln allerdings ausgesetzt.

Happy trading

The Red

[Bocknase]

Previous Page

--------------------------------------------------------------------------------

The Immune Response Corporation Announces a 1-for-4 Reverse Stock Split
Updated: Friday, April 5, 2002 07:11 PM ET Printer-friendly version

CARLSBAD, Calif., April 5 /PRNewswire-FirstCall/ -- The Immune Response Corporation (Nasdaq: IMNR, news, msgs) today announced that its Board of Directors has declared a 1-for-4 reverse stock split relating to its outstanding shares of common stock, subject to approval of the Company`s stockholders at the Company`s annual meeting to be held on May 23, 2002. The Company also intends to seek at its annual meeting, stockholder approval for the issuance by the Company of additional equity securities in connection with a private offering of such securities by Spencer Trask Ventures, Inc. and Wells Fargo Securities. In this regard, the Company has filed with the Securities and Exchange Commission a preliminary proxy statement regarding the foregoing matters.

The Immune Response Corporation is a biopharmaceutical company based in Carlsbad, California, developing immune-based therapies to induce specific immune responses for the treatment of HIV, autoimmune diseases and cancer. In addition, the Company is developing a targeted, non-viral delivery technology for gene therapy, which is designed to enable the delivery of genes directly to the liver via intravenous injection.

NOTE: Company information can also be located on the Internet Web Site: http://www.imnr.com .

This news release contains forward-looking statements. Actual results could vary materially from those expected due to a variety of risk factors, including the uncertainty of successful completion of clinical trials, whether the Company`s stockholders will approve the reverse stock split, whether the Company`s stockholders will approve certain future financings and those risks set forth from time to time in The Immune Response Corporation`s SEC filings, including but not limited to its report on Form 10-K for the year ended December 31, 2001. The Company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements, which may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.